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The question is considered of how and where cytokines, such as interleukin 1 (IL-1), that are
released into the circulation during the host defense response, reach and interact with the central
nervous system to produce fever or act as neuroimmunomodulators. Evidence is presented
suggesting a role for a brain circumventricular organ (CVO) in this respect. Several interactions
between a specific CVO, the organum vasculosum laminae terminalis (OVLT) and endogenous
pyrogen (EP) in the production offever arereviewed. A moregeneral hypothesis isdeveloped on a
role for the brain CVOs in monitoring the blood concentrations of several proteins and complex
polypeptides such as the circulating endocrines that are regulated via the autonomic nervous
system. A proposed connection between the release ofprostaglandin E (PGE) at the blood-brain
interface in response to infection and the ability of the brain to maintain an immunoprivileged
status in the face ofexposureofits CVOs toforeign antigens isdiscussed.
THE BLOOD-BRAIN BARRIER AND THE PATHOGENESIS OF FEVER
During the host defense response to infection or injury, a variety of bone marrow-
derived cells release into the circulation several cytokines, such as interleukins (IL-1
and IL-6) and tumor necrosis factor (TNF), that arecollectively known as endogenous
pyrogen (EP). An important problem in any discussion of the pathogenesis of fever is
whether or not EPenters the brain neuropil fromthecirculation in order toproduce the
activation of thermogenesis and the inhibition of heat loss mechanisms that result in
the characteristic increase in body temperature known as fever. Despite studies using
labeled EP [1] which were unable to demonstrate the presence of EP within the brain
during fever production, it is still widely believed that EP exerts its fever-inducing
effects on the central nervous system (CNS) by entering and acting within the
preoptic/anterior hypothalamic (PO/AH) region of the hypothalamus. It is thought
that EP interacts within the brain neuropil to form the cyclo-oxygenase product
prostaglandin E (PGE), which in turn acts upon the CNS thermoregulatory neurons to
induce fever (see Fig. 1).
There are, however, several reasons to question this particular series ofevents in the
pathogenesis offever. First, studies that haveexamined thedistribution ofsystemically
injected labeled EP [1] or IL-1 [2] both in the brain and the body have shown that,
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FIG. 1. An early hypothesis on the pathogenesis and mechanisms of the
febrile event. A variety of pathogens (activators) stimulate bone marrow-
derived cells to elaborate and release EP into the circulation (1). This
polypeptide travels via the cerebral circulation to the blood-brain barrier,
where it is believed to enter somehow the PO/AH neuropil (2). The EP is
then thought to stimulate the production of prostaglandins from an un-
known cell type within the brain. The prostaglandins such as PGE are then
believed toalterthethermosensitivity oftemperature-sensitive neurons inthe
PO/AH area in such a manner as tocause fever(3).
whilethese labeled cytokines can be readily detected in most peripheral tissues, they do
not appear to cross the blood-brain barrier and enter the brain parenchyma. Second,
there are fundamental differences in the dynamics and timing of fevers that are
produced when EP or IL-I are injected directly into the brain cerebroventricles
compared to when they are injected intravenously. Surprisingly, the latency to fever
onset and the duration offevers induced by the intravenous route are shorter and more
clear-cut than when they are induced by the intracerebroventricular route [3]. This
finding led us to postulate that the site ofaction of EP is closer to the circulation than
the brain neuropil and to consider specialized areas of the cerebral vasculature as
possible sites of entry or action of EP in the production of fever. Particularly
noteworthy in this regard are the seven or eight so-called circumventricular organs
(CVOs), located at various sites within the walls ofthe cerebral ventricles ofthe brain.
These highly vascularized regions are distinct from the brain parenchyma and their
capillaries differ in their permeability properties from the tight-junctioned, non-
fenestrated capillaries that are universally found in the rest ofthe cerebral circulation.
Weindl et al. have published several studies of the relationship between the brain
CVOs and the cerebral circulation on one side, and the brain neuropil on the other.
Using the reaction product of horseradish peroxidase (HRP) as a marker, they have
mapped the distribution of this 45,000 dalton protein within the CVOs and the brain
after it had been injected into the circulation or into the cerebroventricular space
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[4,5,6,7]. Their findings showed that when HRP was injected intravenously (iv), it did
not enter the brain parenchyma, due to the blood-brain barrier. It did appear, however,
to be contained within the interstitial spaces of the CVOs that are found abutting the
cerebroventricular system of the brain. On the other hand, when HRP was injected
intracerebroventricularly (icv), its reaction product distributed uniformly throughout
the entire brain parenchyma but was excluded from the interstitia ofthe CVOs.
This finding led Weindl to conclude that, while the interstitial spaces ofthese CVOs
were in direct contact with the cerebral circulation, they did not permit the passage of
the normally vascular-permeable HRP proteins into the brain neuropil. The capillary
endothelial cells within the CVOs were fenestrated and thus permitted the entry of
HRP into the CVO; however, the impermeability of the brain parenchyma to HRP
from the circulation side of the CVOs was due to the presence of tight-junctioned
ependymal cells surrounding the border between the CVO and the brain neuropil.
These same tight-junctioned ependymal cells also appeared to act as a barrier to the
movement ofHRP from the brain parenchyma into the CVO, when HRP was injected
into the cerebral ventricles. He further postulated that the CVOs might have a role in
either secreting substances into the cerebral circulation or in monitoring the concentra-
tion of complex proteins in the cerebral circulation in connection with the brain's role
of controlling various autonomic endocrine functions [6]. Weindl also described in
some detail the vascular anatomy ofseveral ofthese CVOs [7,8].
THE OVLT AND THE PATHOGENESIS OF FEVER
These observations led us to consider a possible role for one particular CVO, the
organum vasculosum laminae terminalis (OVLT), in connection with the pathogenesis
of fever. The OVLT was chosen because of its proximity to the PO/AH area. Our
initial study consisted of placing discrete electrolytic lesions within the confines of the
OVLT in rabbits and rats in order to ascertain whether these had any effect on the
development of fever in response to intravenously injected EP [9]. Much to our
surprise, we found that these small lesions greatly augmented the febrile response to
EP and that the enhanced febrile responses, which were maximal at between three to
six days after the lesioning, gradually diminished over a period of three to four weeks
(Fig. 2). Appropriate control lesions posited within the PO/AH region had little effect
on fever production. Blatteis and his colleagues [10] also showed that more extensive
lesions encompassing the entire anteroventral wall of the third ventricle (in which
OVLT is located), abolished the febrile responses of guinea pigs that were subse-
quently given intravenous injections of endotoxin pyrogen. They interpreted their
results as showing that pyrogen gained entry into the PO/AH area via the anteroven-
tral region ofthe third ventricle (AV3V) and that lesioningsubsequentlyprevented the
entryofthe pyrogen into the brain. It is equally likely, however, that these much larger
AV3V lesions ablated the entire OVLT and, with it, the receptor sites to EP that
produce PGE (vide infra).
Further research ofthe literature in this area revealed two histological studies on the
composition of the OVLT by Sano, describing the existence of a mesenchymal cell
type, within the interstitium ofthe OVLT, which had phagocytic properties similar to
reticuloendothelial cells and which endocytosed intravenously injected HRP [11,12].
We had also previously observed enhanced febrile responses to EP (iv) in rats several
days after they had been injected intravenously with endotoxin (a lipopolysaccharide
which is known tostimulatephagocytosis inthereticuloendothelial system). Therefore,
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r.0 J crease in rectal temperature ± SEM
0 10 20 30 40 50 60 70 80 90 (all three curves are significantly dif-
Tlme(min) ferent from control curve).
we wondered whether the small lesions that we had made in the OVLT region might
have stimulated phagocytosis in these mesenchymal cells in the OVLT, which in turn
might account for the enhancement ofthe febrile response to EP that we had observed
after the lesioning. Thus, we decided to examine the effect ofinjecting zymosan into
the circulation on EP fever production in rats, since zymosan, in common with other
immunoadjuvants such as lipopolysaccharides (LPS) and muramyl dipeptide (MDP),
is known to stimulate the phagocytic activity of reticuloendothelial cells. We found
that three days after rats were injected with zymosan (30 mg/kg, iv), their febrile
response to an intravenous injection ofEPor IL-I was markedly enhanced. This febrile
enhancement lasted for a period ofseveral weeks (see Fig. 3), gradually declining, in a
manner similar to the fever enhancement we had observed after lesions were placed in
the OVLT. Similar enhancements of EP fever were obtained when rats were pre-
treated with either LPS or MDP, but not when we injected sterile latex beads [13].
To determine whether these immunoadjuvants might be acting at the OVLT region
to produce this enhancement, we implanted rats with microinjection cannulae over the
OVLT region ofthe brain and tested their febrile responses to EP both before and after
1.2
- EP control (2 ml/kg, i.v.) . - EP +3 days after zymosan
1.0 -L --* EP +-10 daysafter zymosan 1.08 0 EP +21 days after zymosan
0.8
ATre 0.L \
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0.4
0.2
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FIG. 3. A study ofthe duration ofthe fever-enhancing effect ofzymosan
pre-treatment in rats (30 mg/kg iv) in response to a standard dose of EP
(2.0 ml/kg iv). Maximum fever enhancement occurred between days 3 and
10 after zymosan treatment and, thereafter, the febrile response declined
toward thefebrile control level. ATre = mean increase in rectal temper-
ature ± SEM (all three curves are significantly different from control
curve).
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FIG. 4. A comparison of the
fever-enhancing effectsofzymo-
san in rats when it is deliv-
ered. A. intravenously (30
mg/kg); B. into the OVLT
(3 ug); C. into the PO/AH
(3 ,ug). Note that the fever en-
hancement produced by intra-
OVLT injection of zymosan
emulates that obtained after in-
travenous injection, whereas in-
tra-PO/AH injection produces
minimal fever enhancement.
ATre = mean increase in rectal
temperature ± SEM; * indi-
catesp > 0.05.
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the introduction ofsmaller (3 ,ug) quantities ofzymosan directly into theOVLTregion.
This treatment produced enhanced febrile responses to EP, similar to those observed
after the iv injection of much larger amounts of zymosan. Injection of identical small
amounts of zymosan into the adjacent PO/AH area or into the cerebroventricular
system had little or no effect on subsequent EP fevers [14]. A summary ofthe results of
these studies is shown in Fig. 4. Similar fever enhancements were also produced by the
introduction oftiny amounts ofLPS and MDP into the OVLT region ofthe rats.
Therefore, we concluded that the immunoadjuvants, which when injected intrave-
ATre
(OC)
0.6
0.4
0.2
1.2
ATre
(OC)
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nously had enhanced EP fevers in rats, were acting at or near the OVLT region and
were making the rats more sensitive to EP. One possible explanation ofthis enhanced
febrile response to EP in rats after immunoadjuvant treatment was that the release of
PGE in response to EP was augmented after immunoadjuvant treatment. We won-
dered ifthe OVLT might be the actual site ofPGE release in response to intravenously
injected EP. It is generally reported that prompt and high fevers are induced when
nanogram quantities ofPGE are microinjected directly into the PO/AH region of the
brain ofnearly all mammalian species [15]. Afirststeptotesting this hypothesis was to
inject PGE into the OVLT rather than into the PO/AH and acertain ifit was capable
ofproducing fever in rats. The results are illustrated in Fig. 5.
Notonlydid PGE producefevers when it was injected into theOVLTregion, but the
fever sensitivity of this area of the brain to PGE far exceeded that of the adjacent
PO/AH region [16]. This result appears to support the hypothesis that the OVLT is
not only the site ofinteraction for EP between the circulation and the brain, but that it
is also the site at which EP causes the release of PGE, which in turn is thought to
produce the febrile response by acting on the neurons in the PO/AH area that regulate
body temperature. The greater sensitivity of the OVLT region to PGE in the produc-
tion of fever in rats suggests that those neurons that are the presumed targets of PGE
must also lie very close to the OVLT, although the relatively small, lipophilic PGE
molecule would have little trouble in penetrating the blood-brain barrier at any
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FIG. 6. A modified hypothesis encompassing the action of cytokines such as IL-1, IL-6, and
TNF in the pathogenesis ofimmune responses, the acute-phase response, and fever. A variety of
pathogens (activators) stimulate bone marrow-derived cells (here represented by a macrophage)
to elaborate and release these cytokines, collectively termed EP, into the circulation. The
mitogenic immune responses and theacute-phase response appear tooccurvia thesystemic action
ofone or more ofthesecytokines. EP also travelsvia thecerebral circulation to theOVLT, where
it is believed tostimulate theproduction ofprostaglandin Efrom an unidentified cell type. PGE is
then thought to enter the adjacent brain neuropil and to cause fever by altering the activity of
temperature-sensitive neurons in thePO/AH area.
location in the cerebral circulation. It may be that the cells described by Murabe et al.
[12] are those which produce PGE in response to circulating EP in the pathogenesis of
fever, although this suggestion awaits direct investigation. Nevertheless, Fig. 6 illus-
trates a modified hypothesis on the hostdefense responseand thepathogenesis offever,
incorporating these recent findings and our current speculations.
While a putative role for a CVO such as the OVLT in the pathogenesis of fever is
intriguing, a larger question of the role of CVOs in general might also be considered.
PROSTAGLANDIN E ' * NEURONS
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For example, is the release of PGE at the OVLT, in response to the cytokines that
comprise EP, solely a link in the pathogenesis offever? Or is itjust one manifestation of
a larger role for PGE and the CVOs in the normal interaction and communication
between the brain and the circulation? Does the release of PGE within the OVLT in
response to circulating EP have any other effect at the blood-brain interface, beyond
the production of fever?
A SENSORY ROLE FOR SOME CIRCUMVENTRICULAR ORGANS?
It is widely believed that a variety of proteins and complex polypeptides concerned
with autonomic function are monitored by central nervous system structures such as
the hypothalamus and septal area [17]. For example, the majority of the circulating
hormones such as thyroxine, corticosteroids, and gonadal hormones, as well as antidi-
uretic hormone and oxytocin, are all postulated to be regulated, either directly or
indirectly, via the hypophyseal gland. Negative feedback signals in the form of
circulating levels of these hormones or their precursor trophic hormones are alleged to
be monitored by the septal, hypothalamic, or hypophyseal areas. For such a feedback
system to function and permit endocrine regulation, the circulating hormones need
access to specific sensory cells that are in turn connected to the brain. Many of these
molecules, like EP, however, do not easily cross the blood-brain barrier. Furthermore,
the necessity of keeping complex molecules out of the brain neuropil seems crucial to
maintaining the immunologically privileged status of brain tissue [18]. There have
been suggestions in the literature that some ofthe brain's CVOs are the sites ofsensory
input for circulating hormones [19,20]. It now seems established that the subfornical
organ (SFO) is the site at which angiotensin II acts to induce drinking in the rat [21],
and that angiotensin II, like EP, does not penetrate the blood-brain barrier into the
brain parenchyma [22]. In a somewhat similar analogy, the brain's emetic center has
been located within the dorsal medullary region, adjacent to another CVO, the area
postrema (AP). It is postulated that circulating toxins that produce vomiting do so by
activating specific chemo-trigger sensory cells within the emetic center and that their
site ofaction is the AP [23].
PROSTAGLANDIN E AND THE IMMUNOPRIVILEGED
STATUS OF THE BRAIN
If these CVOs do in fact act as the brain's "sensory windows" on the circulation,
then they will of necessity come in contact with foreign antigens and other complex
molecules that may from time to time enter the circulation during infection and which
in the normal course of events produce both immune and inflammatory responses in
systemic and peripheral tissues. To prevent this condition, and thereby maintain the
brain's immunoprivileged status, it is suggested that the PGE, released within the CVO
in response to circulating EP, causes an immunosuppression both within the CVO and
perhaps in the brain neuropil immediately surrounding it, which might be exposed to
any of the antigenic material that enters the CVO from the circulation. This effect in
turn would prevent or reduce potentially damaging immune and inflammatory re-
sponses from occurring within the brain tissue itself. In this regard it seems significant
that immunoadjuvants, which enhance the body's immune responses to antigens and
produce heightened titers of antibody to antigen, also appear to augment the release of
PGE in response to the presence of EP at the OVLT and thereby enhance fevers in rats.
There seems ample evidence in the literature to support the idea that PGE has both a
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FIG. 7. A hypothesis ofthe host defense response which incorporates a localized immunosup-
pressive role for the PGE that is released within CVOs such as the OVLT. This role is in addition
to PGE mediation offever, which may be peculiar to the OVLT, because of its proximity to the
PO/AH region.
widespread and profound inhibitory action on most immune system cells [24]. For
example, PGE inhibits the mitogenesis ofT lymphocytes [25] and inhibits the activity
of cytotoxic T cells [26]. It also inhibits the release of lymphokines in response to
antigenic challenge [27] and reduces the production ofantibodies from B lymphocytes
[28]. Furthermore, lysosomal release from polymorphonucleocytes is inhibited by PGE
[29], as is phagocytic enzyme release by macrophages [30]. Finally, it has been shown
that the release ofhistamine from mast cells is also suppressed by PGE [31]. Taken in
total, all evidence appears to show that PGE, at least in vitro, has an immunosuppres-
sive action; however, there is little information about such an action in vivo. This
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situation exists because the action ofPGE is very localized, due to its extremely short
half-life in vivo and the ubiquity ofits catabolic enzymes in all body fluids and tissues.
There may appear to be a paradoxical aspect to the idea of PGE acting as a localized
immunosuppressive agent, since most aspirin-like drugs that inhibit the formation of
prostaglandins alsoinhibit inflammatory responseswhen they areadministered system-
ically. Furthermore, non-steroidal anti-inflammatory drugs,whenadministered system-
ically, do not appear to have any major effect on whole-body immune responses, but
what little in vivo evidence there is tends to support the notion that PGE suppresses
localized immune responses [32]. This paradox has long been recognized [24],
however, and it does not necessarily conflict with the idea of postulating a localized
immunosuppressive action by PGE within the CVOs of the cerebral circulation.
Indeed, one could speculate that the incidence ofReye's syndrome, which is associated
with the administration of aspirin to children suffering otherwise mild infectious or
febrile diseases, might be related to such a phenomenon.
Figure 7 summarizes this postulated role for PGE release within the CVO, incorpo-
rating it into the larger picture of the host defense responses, including the systemic
immune responses, the acute-phase response, and the fever that are produced by
cytokines released from a variety ofcell types in response to injury or infection.
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